AbbVie Sets Biosimilar Expectations As It Prepares To Take The Plunge On Humira
US Brand Erosion Expected To Be 37% In 2023; Amgen Adalimumab Pricing ‘Not A Surprise’
Executive Summary
AbbVie has set out its expectations for US biosimilar competition to Humira this year, predicting 37% brand erosion with pressures ramping up in the second half of 2023 as Amgen’s Amjevita is followed into the market by numerous other adalimumab rivals. Management also commented on pricing dynamics after Amgen offered a dual-discount strategy.
You may also be interested in...
Organon: Adalimumab Sales Won’t Surpass $100m In 2023, Despite US Launch
Organon has provided a relatively clear guide for how its planned launch of a US biosimilar to AbbVie’s Humira in July will impact its top line in 2023, with further detail on the coming years.
Amgen Delivers On Launch Of First US Humira Rival – At A 55% Discount
Amgen has confirmed its long-awaited launch of Amjevita, the first US biosimilar rival to Humira, kicking off a year of competition that will also see a second wave of adalimumab products launch in six months’ time. The company has announced that it will offer the product at a 55% discount to the originator.
Organon Foresees US Adalimumab Discounts Hitting 80%-90%
Organon CEO Kevin Ali has suggested that discounts for US Humira biosimilars could “range anywhere between 80% and 90%” by 2025-2026, amid a slew of competition on adalimumab starting within weeks.